New data presented at 29th ECTRIMS congress reinforce the clinical profile of investigational laquinimod on disease progression and inflammation in relapsing-remitting multiple sclerosis
Teva Pharmaceutical Industries, 4 Oct 2013
Accessed on 4 Oct 2013 from http://ir.tevapharm.com/phoenix.zhtml?c=73925&p=irol-newsArticle&ID=1861679.